BR-1400
/ Boryung Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 21, 2025
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd
New P1 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1